TN2010000126A1 - Antibodies that bind il-4 and/or il-13 and their uses - Google Patents

Antibodies that bind il-4 and/or il-13 and their uses

Info

Publication number: TN2010000126A1
Authority: TN; Tunisia
Prior art keywords: antibodies; bind; fragments; novel; dermatitis
Prior art date: 2007-10-15

Application number

TNP2010000126A

Other languages

English (en)

Inventor

Ercole Rao

Vincent Mikol

Danxi Li

Jochen Kruip

Matthew Davison

Original Assignee

Sanofi Aventis

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2007-10-15

Filing date

2010-03-22

Publication date

2011-09-26

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39313041&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TN2010000126(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2010-03-22 Application filed by Sanofi Aventis filed Critical Sanofi Aventis

2011-09-26 Publication of TN2010000126A1 publication Critical patent/TN2010000126A1/fr

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6845—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a cytokine, e.g. growth factors, VEGF, TNF, a lymphokine or an interferon
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
- C07K16/247—IL-4
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Immunology (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Genetics & Genomics (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pulmonology (AREA)
Epidemiology (AREA)
Wood Science & Technology (AREA)
Biomedical Technology (AREA)
General Engineering & Computer Science (AREA)
Microbiology (AREA)
Biotechnology (AREA)
Zoology (AREA)
Physics & Mathematics (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Plant Pathology (AREA)
Mycology (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)

TNP2010000126A 2007-10-15 2010-03-22 Antibodies that bind il-4 and/or il-13 and their uses TN2010000126A1 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
EP07291259A EP2050764A1 (fr)	2007-10-15	2007-10-15	Nouveau format d'anticorps bispécifique polyvalent
PCT/US2008/079787 WO2009052081A2 (fr)	2007-10-15	2008-10-14	Anticorps se liant à l'il-4 et/ou à l'il-3 et leurs utilisations

Publications (1)

Publication Number	Publication Date
TN2010000126A1 true TN2010000126A1 (en)	2011-09-26

Family

ID=39313041

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
TNP2010000126A TN2010000126A1 (en)	2007-10-15	2010-03-22	Antibodies that bind il-4 and/or il-13 and their uses

Country Status (43)

Country	Link
US (18)	US8388965B2 (fr)
EP (12)	EP2050764A1 (fr)
JP (5)	JP5858616B2 (fr)
KR (5)	KR20190022928A (fr)
CN (3)	CN113480647B (fr)
AR (3)	AR068861A1 (fr)
AU (5)	AU2008312655B2 (fr)
BR (1)	BRPI0818677B8 (fr)
CA (3)	CA3015470C (fr)
CL (4)	CL2008003037A1 (fr)
CR (5)	CR11337A (fr)
CY (5)	CY1114987T1 (fr)
DK (5)	DK2573121T3 (fr)
DO (3)	DOP2010000109A (fr)
ES (5)	ES2647872T3 (fr)
GT (1)	GT201000067A (fr)
HN (1)	HN2010000710A (fr)
HR (5)	HRP20140150T1 (fr)
HU (4)	HUE036530T2 (fr)
IL (2)	IL205005A (fr)
LT (4)	LT2573119T (fr)
MA (1)	MA31838B1 (fr)
MX (6)	MX354150B (fr)
MY (1)	MY171214A (fr)
NI (7)	NI201000402A (fr)
NO (2)	NO2573121T3 (fr)
NZ (3)	NZ584658A (fr)
PA (1)	PA8799001A1 (fr)
PE (1)	PE20091382A1 (fr)
PH (2)	PH12013501032A1 (fr)
PL (5)	PL2573119T3 (fr)
PT (5)	PT2574629T (fr)
RS (5)	RS57396B1 (fr)
RU (4)	RU2580049C2 (fr)
SG (4)	SG10201602770UA (fr)
SI (5)	SI2573119T1 (fr)
TN (1)	TN2010000126A1 (fr)
TR (2)	TR201802225T4 (fr)
TW (4)	TW201825117A (fr)
UA (2)	UA104130C2 (fr)
UY (1)	UY31394A1 (fr)
WO (1)	WO2009052081A2 (fr)
ZA (1)	ZA201002069B (fr)

Families Citing this family (197)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7612181B2 (en)	2005-08-19	2009-11-03	Abbott Laboratories	Dual variable domain immunoglobulin and uses thereof
ES2622460T3 (es)	2007-09-26	2017-07-06	Ucb Biopharma Sprl	Fusiones de anticuerpos con doble especificidad
EP2050764A1 (fr) *	2007-10-15	2009-04-22	sanofi-aventis	Nouveau format d'anticorps bispécifique polyvalent
US20110008345A1 (en) *	2007-11-30	2011-01-13	Claire Ashman	Antigen-binding constructs
US20090162359A1 (en)	2007-12-21	2009-06-25	Christian Klein	Bivalent, bispecific antibodies
US9266967B2 (en)	2007-12-21	2016-02-23	Hoffmann-La Roche, Inc.	Bivalent, bispecific antibodies
MX2011001696A (es) *	2008-08-14	2011-03-25	Merck Sharp & Dohme	Metodos para purificar anticuerpos usando cromatografia de afinidad con proteina a.
EA201100527A1 (ru)	2008-09-26	2011-10-31	Юсб Фарма С.А.	Биологические продукты
PT2417156E (pt)	2009-04-07	2015-04-29	Roche Glycart Ag	Anticorpos trivalentes, biespecíficos
US9676845B2 (en)	2009-06-16	2017-06-13	Hoffmann-La Roche, Inc.	Bispecific antigen binding proteins
EP2475682B1 (fr) *	2009-09-10	2018-01-31	UCB Biopharma SPRL	Anticorps multivalents
JP6091894B2 (ja)	2009-09-16	2017-03-15	ジェネンテック，インコーポレイテッド	コイルドコイルおよび／またはテザー含有タンパク質複合体およびその使用
GB201000467D0 (en) *	2010-01-12	2010-02-24	Ucb Pharma Sa	Antibodies
AR080793A1 (es)	2010-03-26	2012-05-09	Roche Glycart Ag	Anticuerpos biespecificos
FR2958936A1 (fr) *	2010-04-14	2011-10-21	Sanofi Aventis	Proteine de fusion robo1-fc et son utilisation dans le traitement des tumeurs
WO2012009544A2 (fr) *	2010-07-14	2012-01-19	Amgen Inc.	Immunoglobuline à insertion de domaine
CN103154255B (zh)	2010-08-02	2016-04-06	瑞泽恩制药公司	制造包含vl结构域的结合蛋白的小鼠
BR112013002578A2 (pt)	2010-08-03	2019-05-14	Abbvie Inc.	imunoglobinas de domínio variável duplo e usos das mesmas
MX340558B (es)	2010-08-24	2016-07-14	F Hoffmann-La Roche Ag *	Anticuerpos biespecificos que comprenden fragmento fv estabilizado con disulfuro.
CA2807269A1 (fr)	2010-08-24	2012-03-01	Roche Glycart Ag	Anticorps bispecifiques activables
JP5766296B2 (ja)	2010-12-23	2015-08-19	エフ．ホフマン−ラロシュアーゲーＦ．Ｈｏｆｆｍａｎｎ−ＬａＲｏｃｈｅＡｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ	ポリペプチド−ポリヌクレオチド複合体、およびエフェクター成分の標的化された送達におけるその使用
KR101572338B1 (ko)	2011-02-28	2015-11-26	에프. 호프만-라 로슈 아게	1가 항원 결합 단백질
RU2607038C2 (ru)	2011-02-28	2017-01-10	Ф. Хоффманн-Ля Рош Аг	Антигенсвязывающие белки
CN102675460B (zh) *	2011-02-28	2015-08-19	珠海市丽珠单抗生物技术有限公司	抗肿瘤坏死因子α的人源化抗体
US20130344074A1 (en) *	2011-03-16	2013-12-26	Sanofi	Uses of a dual v region antibody-like protein
KR102240802B1 (ko) *	2011-03-28	2021-04-16	사노피	교차 결합 영역 배향을 갖는 이원 가변 영역 항체-유사 결합 단백질
TWI743461B (zh) *	2011-03-28	2021-10-21	法商賽諾菲公司	具有交叉結合區定向之雙重可變區類抗體結合蛋白
WO2012149197A2 (fr)	2011-04-27	2012-11-01	Abbott Laboratories	Procédé de contrôle du profil de galactosylation de protéines exprimées de manière recombinante
EP2710042A2 (fr)	2011-05-16	2014-03-26	Fabion Pharmaceuticals, Inc.	Protéines de fusion contenant un fab multi-spécifique et procédé d'utilisation
UY34105A (es)	2011-06-03	2012-07-31	Lg Life Sciences Ltd	Formulación líquida estable de etanercept
SI2739740T1 (sl)	2011-08-05	2019-12-31	Regeneron Pharmaceuticals, Inc.	Humanizirane univerzalne lahkoverižne miši
UY34317A (es)	2011-09-12	2013-02-28	Genzyme Corp	Anticuerpo antireceptor de célula T (alfa)/ß
PL2782598T3 (pl)	2011-11-23	2021-03-08	In3Bio Ltd.	Rekombinowane białka i ich zastosowania terapeutyczne
WO2013103783A1 (fr) *	2012-01-04	2013-07-11	Sanofi Us	Anticorps murins il-13
MX2014009565A (es)	2012-02-10	2014-11-10	Genentech Inc	Anticuerpos monocatenarios y otros heteromultimeros.
SG11201405830VA (en) *	2012-03-27	2014-10-30	Genentech Inc	Methods of prognosing, diagnosing and treating idiopathic pulmonary fibrosis
WO2013158273A1 (fr)	2012-04-20	2013-10-24	Abbvie Inc.	Procédés de modulation de la distribution de variant de lysine c-terminal
US9150645B2 (en)	2012-04-20	2015-10-06	Abbvie, Inc.	Cell culture methods to reduce acidic species
US9067990B2 (en)	2013-03-14	2015-06-30	Abbvie, Inc.	Protein purification using displacement chromatography
EP2867254B1 (fr)	2012-06-27	2017-10-25	F. Hoffmann-La Roche AG	Procédé de fabrication de conjugués de régions fc comprenant au moins une portion capable de se lier de manière spécifique à une cible et utilisations desdits conjugués
RU2639287C2 (ru)	2012-06-27	2017-12-20	Ф. Хоффманн-Ля Рош Аг	Способ отбора и получения высокоселективных и мультиспецифичных нацеливающих групп с заданными свойствами, включающих по меньшей мере две различные связывающие группировки, и их применения
IL312711A (en)	2012-08-21	2024-07-01	Regeneron Pharma	Methods for the treatment or prevention of asthma through the administration of an antagonist to 4R-IL
US9512214B2 (en)	2012-09-02	2016-12-06	Abbvie, Inc.	Methods to control protein heterogeneity
US9790268B2 (en)	2012-09-12	2017-10-17	Genzyme Corporation	Fc containing polypeptides with altered glycosylation and reduced effector function
DK3366705T5 (da)	2012-09-12	2024-09-30	Genzyme Corp	Fc-indeholdende polypeptider med ændret glycosylering og reduceret effektorfunktion
TW202210507A (zh)	2012-11-01	2022-03-16	美商艾伯維有限公司	抗-vegf/dll4雙重可變區域免疫球蛋白及其用途
EP3466973A1 (fr)	2012-11-01	2019-04-10	AbbVie Inc.	Formulations de protéine immunoglobuline à domaine variable double stable
CN109180815B (zh)	2012-11-20	2022-06-21	赛诺菲	抗ceacam5抗体及其用途
HK1210713A1 (en)	2012-12-27	2016-05-06	Sanofi	Anti-lamp1 antibodies and antibody drug conjugates, and uses thereof
IL319584A (en)	2013-03-11	2025-05-01	Genzyme Corp	Polypeptides with hyperglycosidic bonds
CA2905010A1 (fr)	2013-03-12	2014-09-18	Abbvie Inc.	Anticorps humains qui se lient au tnf-alpha et leurs procedes de preparation
US9017687B1 (en)	2013-10-18	2015-04-28	Abbvie, Inc.	Low acidic species compositions and methods for producing and using the same using displacement chromatography
WO2014151878A2 (fr)	2013-03-14	2014-09-25	Abbvie Inc.	Procédés pour la modulation des profils de glycosylation de protéines de traitements à base de protéines recombinantes au moyen de monosaccharides et d'oligosaccharides
AU2014236769B2 (en) *	2013-03-15	2018-09-27	Amgen Inc.	Heterodimeric bispecific antibodies
EP2968547B1 (fr) *	2013-03-15	2019-08-07	Memorial Sloan Kettering Cancer Center	Technologies de multimérisation
US20140302037A1 (en) *	2013-03-15	2014-10-09	Amgen Inc.	BISPECIFIC-Fc MOLECULES
AR095774A1 (es) *	2013-04-05	2015-11-11	Genentech Inc	Anticuerpos anti-il-4 y anticuerpos biespecíficos y sus usos
TWI679019B (zh)	2013-04-29	2019-12-11	法商賽諾菲公司	抗ｉｌ－４／抗ｉｌ－１３之雙特異性抗體調配物
WO2015051293A2 (fr)	2013-10-04	2015-04-09	Abbvie, Inc.	Utilisation d'ions métalliques pour moduler les profils de glycosylation des protéines dans le cas de protéines recombinées
JP6422956B2 (ja)	2013-10-11	2018-11-14	エフ．ホフマン−ラロシュアーゲーＦ．Ｈｏｆｆｍａｎｎ−ＬａＲｏｃｈｅＡｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ	多重特異性ドメイン交換共通可変軽鎖抗体
US9085618B2 (en)	2013-10-18	2015-07-21	Abbvie, Inc.	Low acidic species compositions and methods for producing and using the same
US9181337B2 (en)	2013-10-18	2015-11-10	Abbvie, Inc.	Modulated lysine variant species compositions and methods for producing and using the same
CA2927099A1 (fr)	2013-10-31	2015-05-07	Sanofi	Anticorps anti-cd38 specifiques pour le traitement de cancers humains
WO2015070014A1 (fr) *	2013-11-08	2015-05-14	Biogen Idec Ma Inc.	Composé de fusion procoagulant
US20150139988A1 (en)	2013-11-15	2015-05-21	Abbvie, Inc.	Glycoengineered binding protein compositions
CA2931113C (fr)	2013-12-20	2023-07-11	Genentech, Inc.	Anticorps comprenant un site de liaison d'antigenes se liant precisementa deux determinants antigeniques differents, et methodes de production
EP2893939A1 (fr)	2014-01-10	2015-07-15	Netris Pharma	Anticorps anti-nétrine-1
WO2015121318A1 (fr) *	2014-02-12	2015-08-20	Sanofi	Formulations de polyglutamate/anticorps bispécifique anti-il-4/anti-il-13
BR112016018980A2 (pt) *	2014-02-21	2017-10-10	Genentech Inc	método de tratamento de um distúrbio, anticorpo multiespecífico, ácido nucleico isolado, célula hospedeira, métodos de produzir um anticorpo, de produção de uma metade de anticorpo ou de um anticorpo multiespecífico e de produção de um anticorpo multiespecífico, imunoconjugado e formulação farmacêutica
IL315136A (en) *	2014-02-21	2024-10-01	Sanofi Biotechnology	Methods for treating or preventing asthma by administering an il-4rantagonist
RS64072B1 (sr)	2014-03-19	2023-04-28	Genzyme Corp	Mesto-specifični glikoinženjering ciljnih delova
CA3124228C (fr)	2014-03-21	2024-05-14	Regeneron Pharmaceuticals, Inc.	Animaux non humains qui produisent des proteines de liaison monodomaine
SG11201607015VA (en)	2014-03-21	2016-09-29	Regeneron Pharma	V<sb>L</sb> ANTIGEN BINDING PROTEINS EXHIBITING DISTINCT BINDING CHARACTERISTICS
TW201628647A (zh) *	2014-06-27	2016-08-16	賽諾菲公司	抗－ｉｌ４－ｉｌ１３雙特異性抗體
SG11201610777VA (en)	2014-07-11	2017-01-27	Genmab As	Antibodies binding axl
WO2016044707A1 (fr)	2014-09-18	2016-03-24	Cedars-Sinai Medical Center	Compositions et procédés de traitement de la fibrose
US10064952B2 (en)	2014-10-09	2018-09-04	Genzyme Corporation	Glycoengineered antibody drug conjugates
RU2734490C2 (ru)	2014-11-14	2020-10-19	Санофи Байотекнолоджи	Способы лечения хронического синусита с полипами носа путем введения антагониста il-4r
JP6686897B2 (ja)	2014-11-21	2020-04-22	アステラス製薬株式会社	新規二重特異的抗体フォーマット
ES2764111T3 (es)	2014-12-03	2020-06-02	Hoffmann La Roche	Anticuerpos multiespecíficos
WO2016094881A2 (fr)	2014-12-11	2016-06-16	Abbvie Inc.	Protéines de liaison à lrp-8
TW202402802A (zh)	2015-01-23	2024-01-16	法商賽諾菲公司	特異性結合ｃｄ３及／或ｃｄ１２３之抗—ｃｄ３抗體，抗—ｃｄ１２３抗體及雙特異性抗體
MA41414A (fr)	2015-01-28	2017-12-05	Centre Nat Rech Scient	Protéines de liaison agonistes d' icos
EP3067062A1 (fr)	2015-03-13	2016-09-14	Ipsen Pharma S.A.S.	Combinaison de tasquinimod ou d'un sel pharmaceutiquement acceptable de celui-ci et d'un inhibiteur de pd1 et/ou de pdl1, destinée à être utilisée comme médicament
CN107430117A (zh) *	2015-03-16	2017-12-01	豪夫迈·罗氏有限公司	检测和定量IL‑13的方法和在诊断和治疗Th2相关疾病中的用途
EP3271403A1 (fr)	2015-03-19	2018-01-24	Regeneron Pharmaceuticals, Inc.	Animaux non humains qui sélectionnent des régions variables de chaînes légères qui se lient à l'antigène
TW201710286A (zh)	2015-06-15	2017-03-16	艾伯維有限公司	抗ｖｅｇｆ、ｐｄｇｆ及／或其受體之結合蛋白
AU2016292762B2 (en)	2015-07-10	2022-07-28	Genmab A/S	AXL-specific antibody-drug conjugates for cancer treatment
MX2018003820A (es)	2015-10-02	2018-12-10	F Hoffmann La Roche Ag	Anticuerpos biespecificos especificos para un receptor de tnf coestimulador.
CN109311966B (zh)	2015-10-25	2023-03-10	赛诺菲	用于预防或治疗hiv感染的三特异性和/或三价结合蛋白
TW201720459A (zh)	2015-11-02	2017-06-16	妮翠斯製藥公司	Ntn1中和劑與抑制後生控制之藥物之組合治療
TW201736399A (zh)	2015-12-31	2017-10-16	財團法人生物技術開發中心	抗vegfr抗體及其應用
MX395252B (es)	2016-01-08	2025-03-25	Altrubio Inc	Anticuerpos tetravalentes anti ligando-1 de glicoproteina p-selectina (psgl-1) y usos de estos.
CA3017776A1 (fr)	2016-03-15	2017-09-21	Generon (Shanghai) Corporation Ltd.	Proteines de fusion a fab multispecifiques et leur utilisation
SI3443006T1 (sl)	2016-04-13	2024-01-31	Sanofi	Trispecifični in/ali trivalentni vezni proteini
JP7195929B2 (ja)	2016-04-13	2022-12-26	サノフイ	三重特異性および／または三価結合タンパク質
WO2017189805A1 (fr)	2016-04-27	2017-11-02	Abbvie Inc.	Méthodes de traitement de maladies dans lesquelles l'activité de l'il-13 est préjudiciable à l'aide d'anticorps anti-il-13
TW201808336A (zh)	2016-05-11	2018-03-16	賽諾菲公司	用抗ｍｕｃ１類美登素免疫綴合物抗體治療腫瘤的治療方案
MA45672A (fr)	2016-07-14	2019-05-22	Biontech Ag	Anticorps multispécifiques dirigés contre cd40 et cd137
TWI790206B (zh)	2016-07-18	2023-01-21	法商賽諾菲公司	特異性結合至ｃｄ３和ｃｄ１２３的雙特異性抗體樣結合蛋白
JP7366742B2 (ja)	2016-08-26	2023-10-23	サノフイ	選択的な軽鎖対形成を容易にする多重特異性抗体
US11286295B2 (en)	2016-10-20	2022-03-29	Sanofi	Anti-CHIKV monoclonal antibodies directed against the E2 structural protein
JP7277363B2 (ja)	2016-11-01	2023-05-18	ジェンマブビー．ブイ．	ポリペプチド変異体およびその使用
US20180164221A1 (en)	2016-12-07	2018-06-14	Progenity Inc.	Gastrointestinal tract detection methods, devices and systems
WO2018127570A1 (fr)	2017-01-05	2018-07-12	Netris Pharma	Traitement combiné à l'aide d'un médicament interférant avec la nétrine-1 et des médicaments inhibiteurs de points de contrôle immunitaires
KR20240049621A (ko)	2017-02-17	2024-04-16	사노피	디스트로글리칸 및 라미닌-2에 대한 특이성을 갖는 다중특이적 결합 분자
US10626169B2 (en)	2017-02-17	2020-04-21	Sanofi	Multispecific binding molecules having specificity to dystroglycan and laminin-2
EP4659808A2 (fr)	2017-02-17	2025-12-10	Sanofi	Molécules de liaison multispécifiques ayant une spécificité pour le dystroglycane et la laminine-2
KR101961871B1 (ko) *	2017-02-20	2019-07-17	주식회사 와이바이오로직스	신규 다중특이적 결합 단백질
WO2018183932A1 (fr)	2017-03-30	2018-10-04	Progenity Inc.	Traitement d'une maladie du tractus gastro-intestinal à l'aide d'un inhibiteur d'il-13
EP3957752B1 (fr) *	2017-04-13	2025-08-20	Regeneron Pharmaceuticals, Inc.	Traitement et inhibition des maladies pulmonaires inflammatoires chez des patients possédant des allèles de risque dans les gènes codant pour l'il33 et il1rl1
US20200247897A1 (en)	2017-06-07	2020-08-06	Genmab B.V.	Therapeutic antibodies based on mutated igg hexamers
KR20200015921A (ko) *	2017-07-03	2020-02-13	재단법인 생물기술개발중심	항-vegfr 항체 및 이의 사용
WO2019028367A1 (fr)	2017-08-04	2019-02-07	Regeneron Pharmaceuticals, Inc.	Méthodes de traitement de l'oesophagite à éosinophiles active
US10849960B2 (en)	2017-09-08	2020-12-01	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Synergistic combination of IL-4, interferon gamma, and interferon alpha in treating ovarian cancer
KR20200061402A (ko)	2017-10-10	2020-06-02	사노피	항-cd38 항체 및 항-cd3 및 항-cd28 항체와의 조합
CN109705217B (zh) *	2017-10-25	2020-09-11	北京智仁美博生物科技有限公司	抗il-13抗体及其用途
KR20250044796A (ko)	2017-10-30	2025-04-01	사노피 바이오테크놀로지	Il-4r 길항제를 투여하여 천식을 치료 또는 예방하는 방법
KR102737364B1 (ko)	2018-01-12	2024-12-05	젠자임 코포레이션	폴리펩티드의 정량화를 위한 방법
EP3743440A1 (fr)	2018-01-24	2020-12-02	Genmab B.V.	Variants polypeptidiques et leurs utilisations
MX2020007882A (es)	2018-01-26	2020-12-03	Genzyme Corp	Variantes fc con unión mejorada a fcrn y semivida prolongada.
CA3096764A1 (fr) *	2018-03-05	2019-09-12	Etablissement Francais Du Sang	Immunoglobulines a chaine unique recombinantes
SG11202008718UA (en) *	2018-03-09	2020-10-29	Brigham & Womens Hospital Inc	Combination therapy for cardiovascular diseases
CN112839958A (zh)	2018-05-03	2021-05-25	根马布私人有限公司	抗体变体组合及其用途
EP3574915A1 (fr)	2018-05-29	2019-12-04	Neovacs	Produit immunogène comprenant de l'il-4 et/ou de l'il-13 pour traiter des troubles associés à une expression ou une activité aberrantes de l'il-4 et/ou de l'il-13
US12275797B2 (en)	2018-06-22	2025-04-15	Genmab Holding B.V.	Anti-CD37 antibodies and anti-CD20 antibodies, compositions and methods of use thereof
MA53123A (fr)	2018-07-13	2021-05-19	Genmab As	Thérapie à médiation par trogocytose utilisant des anticorps cd38
SG11202012993SA (en)	2018-07-13	2021-02-25	Genmab As	Variants of cd38 antibody and uses thereof
EP3847196A4 (fr)	2018-09-07	2023-01-04	ITabMed (HK) Limited	Protéines de liaison à un antigène bispécifiques et leurs utilisations
BR112021006055A2 (pt)	2018-10-04	2021-07-20	Genmab Holding B.V.	composição farmacêutica, uso da composição farmacêutica, e, métodos para induzir a morte celular ou para inibir o crescimento e/ou proliferação de uma célula tumoral e para tratar um indivíduo.
WO2020076853A1 (fr)	2018-10-09	2020-04-16	Sanofi	Protéines de liaison anti-cd38, anti-cd28 et anti-cd3 trispécifiques et procédés d'utilisation pour traiter une infection virale
WO2020096381A1 (fr)	2018-11-09	2020-05-14	아주대학교 산학협력단	Anticorps humain présentant une affinité élevée vis-à-vis du récepteur alpha d'il -4 humain, et son utilisation
WO2020106754A1 (fr)	2018-11-19	2020-05-28	Progenity, Inc.	Méthodes et dispositifs pour traiter une maladie à l'aide d'agents biothérapeutiques
JP7737143B2 (ja)	2018-12-21	2025-09-10	エイム・イムノテック・インコーポレイテッド	がん治療のための組成物および方法
CN110746507B (zh) *	2018-12-25	2020-06-26	江苏荃信生物医药有限公司	抗人白介素4受体α单克隆抗体及其应用
KR20210136071A (ko)	2019-03-06	2021-11-16	리제너론 파아마슈티컬스, 인크.	암을 치료하는데 있어서 증진된 효능을 위한 il-4/il-13 경로 억제제
AU2020240132A1 (en)	2019-03-21	2021-09-16	Regeneron Pharmaceuticals, Inc.	Combination of IL-4/IL-13 pathway inhibitors and plasma cell ablation for treating allergy
CN113939534B (zh)	2019-04-03	2025-02-28	建新公司	具有降低的断裂的抗αβTCR结合多肽
US11613576B2 (en)	2019-04-09	2023-03-28	Sanofi	Trispecific binding proteins, methods, and uses thereof
KR20220012894A (ko)	2019-05-24	2022-02-04	사노피	전신 경화증의 치료 방법
EP3753954A1 (fr)	2019-06-21	2020-12-23	Université de Franche-Comté	Anticorps anti-cd123, récepteurs d'antigène chimériques anti-cd123 et lymphocytes t de récepteurs d'antigène chimériques anti-cd123
AU2020315369A1 (en)	2019-07-16	2022-03-03	Regeneron Pharmaceuticals, Inc.	Methods for treating or preventing asthma by administering an IL-4R antagonist
JP7685985B2 (ja)	2019-07-16	2025-05-30	サノフイ	アルツハイマー病の処置のための中和抗アミロイドベータ抗体
JP2022542884A (ja)	2019-07-25	2022-10-07	ジェンザイム・コーポレーション	Ｆｃｒｎアンタゴニストで抗体媒介性障害を処置する方法
WO2021119482A1 (fr)	2019-12-13	2021-06-17	Progenity, Inc.	Dispositif ingérable pour administrer un agent thérapeutique dans le tractus gastro-intestinal
GB201919062D0 (en) *	2019-12-20	2020-02-05	Ucb Biopharma Sprl	Antibody
JP2023525423A (ja)	2020-01-15	2023-06-16	イマティクスバイオテクノロジーズゲーエムベーハー	Ｐｒａｍｅに特異的に結合する抗原結合タンパク質
JP2023512286A (ja)	2020-01-31	2023-03-24	サノフイ	抗体の肺送達
US11879004B2 (en)	2020-02-28	2024-01-23	Genzyme Corporation	Modified binding polypeptides for optimized drug conjugation
CN115209881A (zh)	2020-03-03	2022-10-18	活跃生物技术有限公司	用于组合疗法的他喹莫德或其药学上可接受的盐
TW202146463A (zh)	2020-03-05	2021-12-16	法商賽諾菲公司	蛋白酶加工的分子
TW202200624A (zh)	2020-03-18	2022-01-01	丹麥商珍美寶股份有限公司	抗體
MX2022013405A (es)	2020-04-24	2022-11-14	Sanofi Sa	Combinaciones antitumorales que contienen productos conjugados de anticuerpos anti-ceacam5 y folfox.
AU2021258465A1 (en)	2020-04-24	2023-01-05	Sanofi	Antitumor combinations containing anti-CEACAM5 antibody conjugates and cetuximab
CN115484989A (zh)	2020-04-24	2022-12-16	赛诺菲	含有抗ceacam5抗体缀合物、曲氟尿苷和三氟尿嘧啶的抗肿瘤组合
US20230087871A1 (en)	2020-04-24	2023-03-23	Sanofi	Antitumor combinations containing anti-ceacam5 antibody conjugates and folfiri
CN111690066B (zh) *	2020-06-22	2022-07-22	南京融捷康生物科技有限公司	抗IL-4Rα的单域抗体以及应用和药物
US20230340067A1 (en) *	2020-06-26	2023-10-26	St. Jude Children's Research Hospital, Inc.	Methods of generating an activation inducible expression system in immune cells
WO2022018294A1 (fr)	2020-07-23	2022-01-27	Genmab B.V.	Combinaison d'anticorps anti-dr5 et d'un médicament à base d'imide immunomodulateur à utiliser dans le traitement du myélome multiple
IL300835A (en)	2020-09-02	2023-04-01	Genmab As	Antibody therapy
IL301004A (en)	2020-09-04	2023-04-01	Merck Patent Gmbh	Anti-ceacam5 antibodies and conjugates and uses thereof
AR125581A1 (es) *	2020-12-07	2023-08-02	UCB Biopharma SRL	Anticuerpos multiespecíficos y combinaciones de anticuerpos
WO2022184805A1 (fr)	2021-03-03	2022-09-09	Immatics Biotechnologies Gmbh	Protéines de liaison à l'antigène se liant spécifiquement à des peptides antigéniques du sars-cov-2 en un complexe avec une protéine du complexe majeur d'histocompatibilité
AU2022268652A1 (en)	2021-05-07	2023-10-05	Genmab A/S	PHARMACEUTICAL COMPOSITIONS COMPRISING BISPECIFIC ANTIBODIES BINDING TO B7H4 and CD3
EP4347640A1 (fr)	2021-05-27	2024-04-10	Sanofi	Variant fc à affinité améliorée vis-à-vis de récepteurs fc et stabilité thermique améliorée
MX2024000002A (es)	2021-07-02	2024-07-09	Merck Patent Gmbh	Anticuerpos y complejos anti-protac.
JPWO2023008404A1 (fr) *	2021-07-26	2023-02-02
AU2022330351A1 (en) *	2021-08-20	2024-04-04	Neovacs	mRNA VACCINES COMPRISING IL-4 AND/OR IL-13 RNA AND USES THEREOF
AU2022382383A1 (en)	2021-11-05	2024-06-20	Eli Lilly And Company	Antitumor combinations containing anti-ceacam5 antibody-drug conjugates and anti-vegfr-2 antibodies
US20230220089A1 (en)	2021-12-30	2023-07-13	Regeneron Pharmaceuticals, Inc.	Methods for attenuating atopic march by administering an il-4/il-13 antagonist
KR20240141208A (ko) *	2022-03-03	2024-09-25	화이자 인코포레이티드	다중특이적 항체 및 그의 용도
EP4489862A1 (fr)	2022-03-09	2025-01-15	Merck Patent GmbH	Anticorps anti-ceacam5 et conjugués et leurs utilisations
EP4245772A1 (fr)	2022-03-18	2023-09-20	Netris Pharma	Anticorps anti-nétrine-1 pour traiter l'inflammation du foie
EP4249509A1 (fr)	2022-03-22	2023-09-27	Netris Pharma	Anticorps anti-nétrine-1 contre la douleur associée à l'arthrite
WO2023227790A1 (fr)	2022-05-27	2023-11-30	Sanofi	Agents d'activation de cellules tueuses naturelles (nk) se liant aux variants nkp46 et bcma avec ingénierie de fc
KR20250025381A (ko)	2022-06-17	2025-02-21	아포지 바이오로직스, 인크.	인터류킨 13에 결합하는 항체 및 사용 방법
TW202432574A (zh)	2022-10-25	2024-08-16	比利時商艾伯霖克斯公司	具有增強的效應子功能之糖基工程化Ｆｃ變體多肽
EP4642482A1 (fr)	2022-12-27	2025-11-05	Merck Patent GmbH	Anticorps anti-protac vhh et complexes
EP4413995A1 (fr)	2023-02-07	2024-08-14	Université de Franche-Comté	Lymphocytes t récepteurs d'antigènes chimériques anti-cd123 pour une utilisation dans le traitement de maladies auto-immunes
WO2024180085A1 (fr)	2023-02-27	2024-09-06	Netris Pharma	Anticorps monoclonal anti-netrine-1 pour le traitement de l'endométriose et de douleurs associées
TW202502387A (zh)	2023-03-01	2025-01-16	法商賽諾菲公司	抗ceacam5免疫接合物用於治療表現ceacam5的神經內分泌癌症之用途
EP4427763A1 (fr)	2023-03-06	2024-09-11	Sanofi	Combinaisons antitumorales contenant des conjugués anticorps anti-ceacam5-médicament, anticorps anti-vegfr-2 et anticorps anti-pd1/pd-l1
AU2024240376A1 (en)	2023-03-23	2025-11-06	Sanofi	CEACAM5 mRNA ASSAY FOR PATIENT SELECTION IN CANCER THERAPY
EP4434586A1 (fr)	2023-03-23	2024-09-25	Xenothera	Combinaison d'anticorps, ou de fragments de liaison à l'antigène de ceux-ci, pour le traitement du cancer et composition associée
WO2024235862A1 (fr)	2023-05-12	2024-11-21	Genmab A/S	Anticorps capables de se lier à cd27, variants de ceux-ci et leurs utilisations
WO2024238614A2 (fr) *	2023-05-15	2024-11-21	Sthria Sciences Limited Liability Company	Méthode de traitement d'une maladie auto-immune
WO2024251733A1 (fr)	2023-06-05	2024-12-12	Sanofi	Combinaisons antitumorales contenant des conjugués anticorps anti-ceacam5-médicament, des anticorps anti-pd1/pd-l1 et des anticorps anti-ctla4
WO2025049347A1 (fr) *	2023-08-25	2025-03-06	Triveni Bio, Inc.	Anticorps ciblant klk5/7 + il-4 et leurs utilisations
WO2025049345A1 (fr)	2023-08-25	2025-03-06	Proteologix Us Inc.	Constructions d'anticorps multispécifiques anti-il-13 et leurs utilisations
WO2025049346A1 (fr) *	2023-08-25	2025-03-06	Triveni Bio, Inc.	Anticorps ciblant klk5/7 + th2 et leurs utilisations
WO2025049348A1 (fr) *	2023-08-25	2025-03-06	Triveni Bio, Inc.	Anticorps ciblant klk5/7 + il-13 et leurs utilisations
JP2025036273A (ja) *	2023-08-30	2025-03-14	ファイザー・インク	多重特異性抗体およびその使用
WO2025073856A1 (fr)	2023-10-04	2025-04-10	Xenothera	Association d'anticorps ou de fragments de liaison à l'antigène associés pour le traitement de cancers
WO2025088546A1 (fr)	2023-10-25	2025-05-01	Ablynx N.V.	Variants de domaine fc avec liaison de récepteur fc améliorée
WO2025166138A1 (fr) *	2024-02-02	2025-08-07	Triveni Bio, Inc.	Anticorps ciblant klk5/7 + tslp et leurs utilisations
WO2025166146A1 (fr) *	2024-02-02	2025-08-07	Triveni Bio, Inc.	Anticorps ciblant klk5/7 + ox40 et leurs utilisations
WO2025242845A1 (fr)	2024-05-22	2025-11-27	Merck Patent Gmbh	Traitement du cancer colorectal

Family Cites Families (144)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3773919A (en)	1969-10-23	1973-11-20	Du Pont	Polylactide-drug mixtures
US4179337A (en)	1973-07-20	1979-12-18	Davis Frank F	Non-immunogenic polypeptides
US4307016A (en)	1978-03-24	1981-12-22	Takeda Chemical Industries, Ltd.	Demethyl maytansinoids
US4275149A (en)	1978-11-24	1981-06-23	Syva Company	Macromolecular environment control in specific receptor assays
US4318980A (en)	1978-04-10	1982-03-09	Miles Laboratories, Inc.	Heterogenous specific binding assay employing a cycling reactant as label
US4256746A (en) *	1978-11-14	1981-03-17	Takeda Chemical Industries	Dechloromaytansinoids, their pharmaceutical compositions and method of use
JPS55102583A (en)	1979-01-31	1980-08-05	Takeda Chem Ind Ltd	20-acyloxy-20-demethylmaytansinoid compound
JPS55162791A (en)	1979-06-05	1980-12-18	Takeda Chem Ind Ltd	Antibiotic c-15003pnd and its preparation
JPS6023084B2 (ja)	1979-07-11	1985-06-05	味の素株式会社	代用血液
JPS5645483A (en)	1979-09-19	1981-04-25	Takeda Chem Ind Ltd	C-15003phm and its preparation
JPS5645485A (en)	1979-09-21	1981-04-25	Takeda Chem Ind Ltd	Production of c-15003pnd
EP0028683A1 (fr)	1979-09-21	1981-05-20	Takeda Chemical Industries, Ltd.	Antibiotique C-15003 PHO et sa préparation
US4444887A (en)	1979-12-10	1984-04-24	Sloan-Kettering Institute	Process for making human antibody producing B-lymphocytes
US4376110A (en) *	1980-08-04	1983-03-08	Hybritech, Incorporated	Immunometric assays using monoclonal antibodies
WO1982001188A1 (fr)	1980-10-08	1982-04-15	Takeda Chemical Industries Ltd	Composes 4,5-deoxymaytansinoide et leur procede de preparation
US4450254A (en)	1980-11-03	1984-05-22	Standard Oil Company	Impact improvement of high nitrile resins
US4313946A (en)	1981-01-27	1982-02-02	The United States Of America As Represented By The Secretary Of Agriculture	Chemotherapeutically active maytansinoids from Trewia nudiflora
US4315929A (en)	1981-01-27	1982-02-16	The United States Of America As Represented By The Secretary Of Agriculture	Method of controlling the European corn borer with trewiasine
JPS57192389A (en)	1981-05-20	1982-11-26	Takeda Chem Ind Ltd	Novel maytansinoid
US4640835A (en)	1981-10-30	1987-02-03	Nippon Chemiphar Company, Ltd.	Plasminogen activator derivatives
US4716111A (en)	1982-08-11	1987-12-29	Trustees Of Boston University	Process for producing human antibodies
US4560655A (en)	1982-12-16	1985-12-24	Immunex Corporation	Serum-free cell culture medium and process for making same
US4657866A (en)	1982-12-21	1987-04-14	Sudhir Kumar	Serum-free, synthetic, completely chemically defined tissue culture media
GB8308235D0 (en) *	1983-03-25	1983-05-05	Celltech Ltd	Polypeptides
US4816567A (en)	1983-04-08	1989-03-28	Genentech, Inc.	Recombinant immunoglobin preparations
US4767704A (en)	1983-10-07	1988-08-30	Columbia University In The City Of New York	Protein-free culture medium
US4496689A (en)	1983-12-27	1985-01-29	Miles Laboratories, Inc.	Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
US5807715A (en)	1984-08-27	1998-09-15	The Board Of Trustees Of The Leland Stanford Junior University	Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
WO1986005807A1 (fr)	1985-04-01	1986-10-09	Celltech Limited	Lignee cellulaire de myelomes transformee et procede d'expression d'un gene codant un polypeptide eucaryotque employant cette lignee
US4737456A (en)	1985-05-09	1988-04-12	Syntex (U.S.A.) Inc.	Reducing interference in ligand-receptor binding assays
DE3675588D1 (de)	1985-06-19	1990-12-20	Ajinomoto Kk	Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist.
US4676980A (en)	1985-09-23	1987-06-30	The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services	Target specific cross-linked heteroantibodies
US5618920A (en)	1985-11-01	1997-04-08	Xoma Corporation	Modular assembly of antibody genes, antibodies prepared thereby and use
GB8601597D0 (en) *	1986-01-23	1986-02-26	Wilson R H	Nucleotide sequences
JPS63502716A (ja)	1986-03-07	1988-10-13	マサチューセッツ・インステチュート・オブ・テクノロジー	糖タンパク安定性の強化方法
US5225539A (en)	1986-03-27	1993-07-06	Medical Research Council	Recombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en)	1986-03-27	1986-04-30	Winter G P	Recombinant dna product
US4791192A (en)	1986-06-26	1988-12-13	Takeda Chemical Industries, Ltd.	Chemically modified protein with polyethyleneglycol
US4946778A (en)	1987-09-21	1990-08-07	Genex Corporation	Single polypeptide chain binding molecules
GB8717430D0 (en)	1987-07-23	1987-08-26	Celltech Ltd	Recombinant dna product
IL89489A0 (en)	1988-03-09	1989-09-10	Hybritech Inc	Chimeric antibodies directed against human carcinoembryonic antigen
KR900700134A (ko)	1988-04-15	1990-08-11	원본미기재	Il-2 수용체-특이적 키메릭 항체
JP3105898B2 (ja)	1988-04-16	2000-11-06	セルテックリミテッド	組換えｄｎａタンパクの製造方法
AU631802B2 (en)	1988-06-14	1992-12-10	Cetus Oncology Corporation	Coupling agents and sterically hindered disulfide linked conjugates prepared therefrom
US5223409A (en)	1988-09-02	1993-06-29	Protein Engineering Corp.	Directed evolution of novel binding proteins
US6048728A (en)	1988-09-23	2000-04-11	Chiron Corporation	Cell culture medium for enhanced cell growth, culture longevity, and product expression
US5534617A (en)	1988-10-28	1996-07-09	Genentech, Inc.	Human growth hormone variants having greater affinity for human growth hormone receptor at site 1
EP0368684B2 (fr)	1988-11-11	2004-09-29	Medical Research Council	Clonage de séquences d'immunoglobulines de domaines variables.
US5530101A (en)	1988-12-28	1996-06-25	Protein Design Labs, Inc.	Humanized immunoglobulins
ZA902949B (en)	1989-05-05	1992-02-26	Res Dev Foundation	A novel antibody delivery system for biological response modifiers
CA2018228C (fr)	1989-06-05	1996-02-27	Nancy L. Parenteau	Systemes et milieu de culture cellulaire
US5413923A (en)	1989-07-25	1995-05-09	Cell Genesys, Inc.	Homologous recombination for universal donor cells and chimeric mammalian hosts
FR2650598B1 (fr)	1989-08-03	1994-06-03	Rhone Poulenc Sante	Derives de l'albumine a fonction therapeutique
GB8928874D0 (en)	1989-12-21	1990-02-28	Celltech Ltd	Humanised antibodies
ES2284161T3 (es)	1990-01-12	2007-11-01	Amgen Fremont Inc.	Generacion de anticuerpos xenogenicos.
US5314995A (en)	1990-01-22	1994-05-24	Oncogen	Therapeutic interleukin-2-antibody based fusion proteins
EP0521985B1 (fr)	1990-03-20	1997-09-24	The Trustees Of Columbia University In The City Of New York	Anticorps chimeriques utilisant des ligands de liaison de recepteurs a la place de leur region constante
GB9015198D0 (en)	1990-07-10	1990-08-29	Brien Caroline J O	Binding substance
US5814318A (en)	1990-08-29	1998-09-29	Genpharm International Inc.	Transgenic non-human animals for producing heterologous antibodies
US5661016A (en)	1990-08-29	1997-08-26	Genpharm International Inc.	Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5633425A (en)	1990-08-29	1997-05-27	Genpharm International, Inc.	Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en)	1990-08-29	1996-08-13	Genpharm International, Inc.	Ransgenic non-human animals for producing heterologous antibodies
US5625126A (en)	1990-08-29	1997-04-29	Genpharm International, Inc.	Transgenic non-human animals for producing heterologous antibodies
DE69133476T2 (de)	1990-08-29	2006-01-05	GenPharm International, Inc., Palo Alto	Transgene Mäuse fähig zur Produktion heterologer Antikörper
US5122469A (en) *	1990-10-03	1992-06-16	Genentech, Inc.	Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
ES2178635T3 (es)	1990-11-09	2003-01-01	Stephen D Gillies	Inmunoconjugados de citoquinas.
DE69233482T2 (de)	1991-05-17	2006-01-12	Merck & Co., Inc.	Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
ES2136092T3 (es) *	1991-09-23	1999-11-16	Medical Res Council	Procedimientos para la produccion de anticuerpos humanizados.
WO1993008829A1 (fr)	1991-11-04	1993-05-13	The Regents Of The University Of California	Compositions induisant la destruction de cellules infectees par l'hiv
ATE297465T1 (de)	1991-11-25	2005-06-15	Enzon Inc	Verfahren zur herstellung von multivalenten antigenbindenden proteinen
ES2341666T3 (es)	1991-12-02	2010-06-24	Medimmune Limited	Produccion de autoanticuerpos de repertorios de segmentos de anticue rpos expresados en la superficie de fagos.
US5869619A (en)	1991-12-13	1999-02-09	Xoma Corporation	Modified antibody variable domains
FR2686901A1 (fr)	1992-01-31	1993-08-06	Rhone Poulenc Rorer Sa	Nouveaux polypeptides antithrombotiques, leur preparation et compositions pharmaceutiques les contenant.
FR2686899B1 (fr)	1992-01-31	1995-09-01	Rhone Poulenc Rorer Sa	Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
ATE295420T1 (de)	1992-02-06	2005-05-15	Chiron Corp	Marker für krebs und biosynthetisches bindeprotein dafür
ES2149768T3 (es)	1992-03-25	2000-11-16	Immunogen Inc	Conjugados de agentes enlazantes de celulas derivados de cc-1065.
AU4025193A (en)	1992-04-08	1993-11-18	Cetus Oncology Corporation	Humanized C-erbB-2 specific antibodies
ZA932522B (en)	1992-04-10	1993-12-20	Res Dev Foundation	Immunotoxins directed against c-erbB-2(HER/neu) related surface antigens
KR970000862B1 (ko)	1992-06-09	1997-01-20	호프 아크티엔게젤샤프트	래치 및 잠금장치
WO1994004670A1 (fr)	1992-08-26	1994-03-03	President And Fellows Of Harvard College	Utilisation de la cytokine ip-10 comme agent antitumeur
US5639641A (en)	1992-09-09	1997-06-17	Immunogen Inc.	Resurfacing of rodent antibodies
WO1994025591A1 (fr)	1993-04-29	1994-11-10	Unilever N.V.	PRODUCTION D'ANTICORPS OU DE FRAGMENTS FONCTIONNALISES D'ANTICORPS, DERIVES DES IMMUNOGLOBULINES A CHAINE LOURDE DE $i(CAMELIDAE)
UA48940C2 (uk)	1993-09-07	2002-09-16	Смітклайн Бічам Корпорейшн	Рекомбінатні il4 антитіла, які використовуються для лікування il4-опосередкованих порушень
US20020193575A1 (en)	1993-09-07	2002-12-19	Smithkline Beecham P.L.C.	Recombinant IL4 antibodies useful in treatment of IL4 mediated disorders
US5928904A (en) *	1993-09-07	1999-07-27	Smithkline Beecham Corporation	DNA encoding recombinant IL4 antibodies useful in treatment of IL4 mediated disorders
ZA946875B (en) *	1993-09-07	1995-07-06	Smithkline Beecham Corp	Recombinant il4 antibodies useful in treatment of il4 mediated disorders
WO1995009917A1 (fr) *	1993-10-07	1995-04-13	The Regents Of The University Of California	Anticorps bispecifiques et tetravalents, obtenus par genie genetique
US5597710A (en)	1994-03-10	1997-01-28	Schering Corporation	Humanized monoclonal antibodies against human interleukin-4
US5705154A (en)	1995-03-08	1998-01-06	Schering Corporation	Humanized monoclonal antibodies against human interleukin-4
US6165463A (en)	1997-10-16	2000-12-26	Inhale Therapeutic Systems, Inc.	Dispersible antibody compositions and methods for their preparation and use
ATE390933T1 (de)	1995-04-27	2008-04-15	Amgen Fremont Inc	Aus immunisierten xenomäusen stammende menschliche antikörper gegen il-8
EP0823941A4 (fr)	1995-04-28	2001-09-19	Abgenix Inc	Anticorps humains derives de xeno-souris immunisees
BR9606706A (pt)	1995-10-16	1999-04-06	Unilever Nv	Análogo de fragmento de anticorpo biespecífico ou bivalente uso processo para produzir o mesmo
US6664227B1 (en)	1996-03-01	2003-12-16	Genetics Institute, Llc	Treatment of fibrosis by antagonism of IL-13 and IL-13 receptor chains
AU5711196A (en)	1996-03-14	1997-10-01	Human Genome Sciences, Inc.	Apoptosis inducing molecule i
EP0904107B1 (fr)	1996-03-18	2004-10-20	Board Of Regents, The University Of Texas System	Domaines analogues a l'immunoglobuline a demi-vies prolongees
KR20030096450A (ko)	1996-03-22	2003-12-31	휴먼 게놈 사이언시즈, 인코포레이티드	고사 유도 분자 ⅱ
AU729406B2 (en)	1996-03-28	2001-02-01	Johns Hopkins University, The	Soluble divalent and multivalent heterodimeric analogs of proteins
US5916771A (en)	1996-10-11	1999-06-29	Abgenix, Inc.	Production of a multimeric protein by cell fusion method
WO1998023289A1 (fr)	1996-11-27	1998-06-04	The General Hospital Corporation	Modulation de la fixation de l'igg au fcrn
DK1500329T3 (da)	1996-12-03	2012-07-09	Amgen Fremont Inc	Humane antistoffer, der specifikt binder TNF-alfa
GB9625899D0 (en) *	1996-12-13	1997-01-29	Glaxo Group Ltd	Substances and their uses
US6277375B1 (en)	1997-03-03	2001-08-21	Board Of Regents, The University Of Texas System	Immunoglobulin-like domains with increased half-lives
DK0970126T3 (da)	1997-04-14	2001-08-13	Micromet Ag	Hidtil ukendt fremgangsmåde til fremstillingen af anti-humant antigen-receptorer og anvendelser deraf
US6235883B1 (en)	1997-05-05	2001-05-22	Abgenix, Inc.	Human monoclonal antibodies to epidermal growth factor receptor
MXPA00004256A (es)	1997-11-03	2005-07-01	Human Genome Sciences Inc	Inhibidor de las celulas endoteliales vasculares, un inhibidor de la angiogenesis y crecimiento del tumor.
WO2000018435A1 (fr)	1998-09-25	2000-04-06	Horst Lindhofer	Utilisation de cellules tumorales avec un decalage temporel en combinaison avec des anticorps intacts pour l'immunisation
DK2168984T3 (da) *	1999-03-25	2012-12-10	Abbott Gmbh & Co Kg	Humane antistoffer, som binder humant IL-12, og fremgangsmåder til pro-duktion heraf
MXPA02010011A (es)	2000-04-11	2003-04-25	Genentech Inc	Anticuerpos multivalentes y usos para los mismos.
ES2484966T3 (es)	2000-04-12	2014-08-12	Novozymes Biopharma Dk A/S	Proteínas de fusión de albúmina
EP1299419A2 (fr) *	2000-05-24	2003-04-09	Imclone Systems, Inc.	Proteines bispecifiques de liaison a l'antigene du type immunoglobulines, et procede de production correspondant
CA2417185A1 (fr) *	2000-07-25	2002-01-31	Shui-On Leung	Proteine de liaison cible multivalente
US6333410B1 (en)	2000-08-18	2001-12-25	Immunogen, Inc.	Process for the preparation and purification of thiol-containing maytansinoids
RU2430927C2 (ru) *	2000-10-20	2011-10-10	Тугаи Сейяку Кабусики Кайся	Агонистическое соединение, способное специфически узнавать и поперечно сшивать молекулу клеточной поверхности или внутриклеточную молекулу
WO2003035847A2 (fr)	2001-10-26	2003-05-01	Centocor, Inc.	Proteines muteines il-13, anticorps, compositions, procedes et utilisations
US20040023338A1 (en)	2001-10-26	2004-02-05	Heavner George A.	IL-4 mutein proteins, antibodies, compositions, methods and uses
EP1499354A4 (fr)	2002-05-01	2007-07-25	Regeneron Pharma	Procedes d'utilisation des antagonistes des cytokines dans le traitement de l'infection par le vih et le sida
US20070104710A1 (en) *	2002-06-28	2007-05-10	Domants Limited	Ligand that has binding specificity for IL-4 and/or IL-13
CA2522819A1 (fr) *	2003-04-22	2004-11-04	Immunomedics, Inc.	Complexe proteinique polyvalent
GB0407315D0 (en)	2003-07-15	2004-05-05	Cambridge Antibody Tech	Human antibody molecules
UA93653C2 (ru) *	2003-11-07	2011-03-10	Иммунекс Корпорейшн	Выделенное антитело, kotopoe специфически связывается c человеческим рецептором il-4 (il-4r)
SG10201900535UA (en) *	2003-12-23	2019-02-27	Genentech Inc	Novel anti-il 13 antibodies and uses thereof
US7652146B2 (en)	2004-02-06	2010-01-26	Bristol-Myers Squibb Company	Process for preparing 2-aminothiazole-5-carboxamides useful as kinase inhibitors
JP5010923B2 (ja)	2004-02-09	2012-08-29	ヒューマンジノームサイエンシーズ，インコーポレイテッド	アルブミン融合蛋白質
EP1723428A2 (fr) *	2004-02-19	2006-11-22	Yale University Corporation	Identification de biomarqueurs proteiques du cancer par des techniques proteomiques
US7410781B2 (en)	2004-02-27	2008-08-12	Regeneron Pharmaceuticals, Inc.	IL-4/IL-13 specific polypeptides and therapeutic uses thereof
GB0411186D0 (en) *	2004-05-19	2004-06-23	Celltech R&D Ltd	Biological products
DK1765397T3 (da) *	2004-05-25	2013-02-04	Tactic Pharma Llc	Inhiberende antistoffer, som binder komplekset af urokinase-type-plasminogenaktivator (uPA) og dens receptor (uPAR)
AR049390A1 (es) *	2004-06-09	2006-07-26	Wyeth Corp	Anticuerpos contra la interleuquina-13 humana y usos de los mismos
GB0414799D0 (en) *	2004-07-01	2004-08-04	Glaxo Group Ltd	Immunoglobulins
US20060148009A1 (en)	2004-10-12	2006-07-06	Xencor, Inc.	Prediction and assessment of immunogenicity
TWI306862B (en) *	2005-01-03	2009-03-01	Hoffmann La Roche	Antibodies against il-13 receptor alpha 1 and uses thereof
WO2006117910A1 (fr) *	2005-04-28	2006-11-09	Mochida Pharmaceutical Co., Ltd.	Anticorps monoclonal contre la glycoproteine vi de la membrane de la plaquette
GB0514319D0 (en) *	2005-07-13	2006-06-14	Secr Defence	Antibodies for anthrax
US7612181B2 (en) *	2005-08-19	2009-11-03	Abbott Laboratories	Dual variable domain immunoglobulin and uses thereof
AU2006296399B2 (en)	2005-09-30	2011-01-20	Medimmune Limited	Interleukin-13 antibody composition
EP1957530A2 (fr) *	2005-10-21	2008-08-20	Novartis AG	Anticorps humains contre l'il-13 et ses utilisations therapeutiques
GB0600488D0 (en) *	2006-01-11	2006-02-22	Glaxo Group Ltd	Immunoglobulins
AU2007209202A1 (en)	2006-01-24	2007-08-02	Domantis Limited	Ligands that bind IL-4 and/or IL-13
AU2007228943B2 (en) *	2006-03-22	2012-03-22	Apogenix Gmbh	Antibody specific for human IL-4 for the treament of cancer
EP2050764A1 (fr)	2007-10-15	2009-04-22	sanofi-aventis	Nouveau format d'anticorps bispécifique polyvalent
US20130344074A1 (en) *	2011-03-16	2013-12-26	Sanofi	Uses of a dual v region antibody-like protein
TWI679019B (zh) *	2013-04-29	2019-12-11	法商賽諾菲公司	抗ｉｌ－４／抗ｉｌ－１３之雙特異性抗體調配物
TW201628647A (zh) *	2014-06-27	2016-08-16	賽諾菲公司	抗－ｉｌ４－ｉｌ１３雙特異性抗體

2007
- 2007-10-15 EP EP07291259A patent/EP2050764A1/fr not_active Ceased
2008
- 2008-10-13 PE PE2008001760A patent/PE20091382A1/es active IP Right Grant
- 2008-10-14 CN CN202110668094.XA patent/CN113480647B/zh active Active
- 2008-10-14 BR BRPI0818677A patent/BRPI0818677B8/pt active IP Right Grant
- 2008-10-14 MX MX2012002053A patent/MX354150B/es unknown
- 2008-10-14 LT LTEP12006797.0T patent/LT2573119T/lt unknown
- 2008-10-14 KR KR1020197005667A patent/KR20190022928A/ko not_active Ceased
- 2008-10-14 ES ES12006790.5T patent/ES2647872T3/es active Active
- 2008-10-14 RU RU2013120318/10A patent/RU2580049C2/ru active
- 2008-10-14 RS RS20180809A patent/RS57396B1/sr unknown
- 2008-10-14 EP EP12006796A patent/EP2573118A1/fr not_active Withdrawn
- 2008-10-14 US US12/682,864 patent/US8388965B2/en active Active
- 2008-10-14 ES ES12006797.0T patent/ES2664476T3/es active Active
- 2008-10-14 HR HRP20140150AT patent/HRP20140150T1/hr unknown
- 2008-10-14 PT PT120067897T patent/PT2574629T/pt unknown
- 2008-10-14 NZ NZ584658A patent/NZ584658A/xx unknown
- 2008-10-14 MY MYPI2010001251A patent/MY171214A/en unknown
- 2008-10-14 CA CA3015470A patent/CA3015470C/fr active Active
- 2008-10-14 TR TR2018/02225T patent/TR201802225T4/tr unknown
- 2008-10-14 MX MX2010003290A patent/MX2010003290A/es active IP Right Grant
- 2008-10-14 SI SI200831938T patent/SI2573119T1/en unknown
- 2008-10-14 EP EP12006797.0A patent/EP2573119B1/fr active Active
- 2008-10-14 JP JP2010530058A patent/JP5858616B2/ja active Active
- 2008-10-14 RS RS20180381A patent/RS57060B1/sr unknown
- 2008-10-14 SI SI200831976T patent/SI2574630T1/en unknown
- 2008-10-14 EP EP12006794A patent/EP2573116A1/fr not_active Ceased
- 2008-10-14 SI SI200831156T patent/SI2205640T1/sl unknown
- 2008-10-14 HU HUE12006789A patent/HUE036530T2/hu unknown
- 2008-10-14 CN CN200880111668.6A patent/CN101827863B/zh active Active
- 2008-10-14 SG SG10201602770UA patent/SG10201602770UA/en unknown
- 2008-10-14 PL PL12006797T patent/PL2573119T3/pl unknown
- 2008-10-14 EP EP12006792A patent/EP2573115A1/fr not_active Ceased
- 2008-10-14 KR KR1020187002319A patent/KR101954596B1/ko active Active
- 2008-10-14 UA UAA201005855A patent/UA104130C2/uk unknown
- 2008-10-14 EP EP19214415.2A patent/EP3686220A1/fr active Pending
- 2008-10-14 KR KR1020167033258A patent/KR101823859B1/ko active Active
- 2008-10-14 PL PL12006790T patent/PL2573121T3/pl unknown
- 2008-10-14 NO NO12006790A patent/NO2573121T3/no unknown
- 2008-10-14 CN CN201710131539.4A patent/CN106986938B/zh active Active
- 2008-10-14 DK DK12006790.5T patent/DK2573121T3/en active
- 2008-10-14 TR TR2018/10005T patent/TR201810005T4/tr unknown
- 2008-10-14 CL CL2008003037A patent/CL2008003037A1/es unknown
- 2008-10-14 UA UAA201310544A patent/UA118949C2/uk unknown
- 2008-10-14 HU HUE12006791A patent/HUE038444T2/hu unknown
- 2008-10-14 HU HUE12006797A patent/HUE038556T2/hu unknown
- 2008-10-14 HU HUE12006790A patent/HUE037205T2/hu unknown
- 2008-10-14 DK DK08839958.9T patent/DK2205640T3/en active
- 2008-10-14 PT PT88399589T patent/PT2205640E/pt unknown
- 2008-10-14 WO PCT/US2008/079787 patent/WO2009052081A2/fr not_active Ceased
- 2008-10-14 EP EP12006795A patent/EP2573117A1/fr not_active Withdrawn
- 2008-10-14 AU AU2008312655A patent/AU2008312655B2/en active Active
- 2008-10-14 KR KR1020147024155A patent/KR101682373B1/ko active Active
- 2008-10-14 ES ES12006789.7T patent/ES2660152T3/es active Active
- 2008-10-14 LT LTEP12006791.3T patent/LT2574630T/lt unknown
- 2008-10-14 PT PT120067970T patent/PT2573119T/pt unknown
- 2008-10-14 DK DK12006789.7T patent/DK2574629T3/en active
- 2008-10-14 PL PL12006789T patent/PL2574629T3/pl unknown
- 2008-10-14 RS RS20180201A patent/RS56914B1/sr unknown
- 2008-10-14 EP EP12006790.5A patent/EP2573121B1/fr active Active
- 2008-10-14 AR ARP080104471A patent/AR068861A1/es active IP Right Grant
- 2008-10-14 SG SG2012076568A patent/SG185303A1/en unknown
- 2008-10-14 EP EP08839958.9A patent/EP2205640B1/fr active Active
- 2008-10-14 SI SI200831890T patent/SI2573121T1/en unknown
- 2008-10-14 SG SG10201913836SA patent/SG10201913836SA/en unknown
- 2008-10-14 RU RU2010119521/10A patent/RU2488595C2/ru active
- 2008-10-14 RS RS20171174A patent/RS56553B1/sr unknown
- 2008-10-14 EP EP12006793A patent/EP2574626A1/fr not_active Withdrawn
- 2008-10-14 ES ES08839958.9T patent/ES2447915T3/es active Active
- 2008-10-14 MX MX2012002055A patent/MX363638B/es unknown
- 2008-10-14 MX MX2012010172A patent/MX363901B/es unknown
- 2008-10-14 NZ NZ709353A patent/NZ709353A/en unknown
- 2008-10-14 LT LTEP12006790.5T patent/LT2573121T/lt unknown
- 2008-10-14 DK DK12006797.0T patent/DK2573119T3/en active
- 2008-10-14 RS RS20140077A patent/RS53175B/sr unknown
- 2008-10-14 CA CA2702473A patent/CA2702473C/fr active Active
- 2008-10-14 LT LTEP12006789.7T patent/LT2574629T/lt unknown
- 2008-10-14 SG SG10201913838RA patent/SG10201913838RA/en unknown
- 2008-10-14 NZ NZ601342A patent/NZ601342A/en unknown
- 2008-10-14 KR KR1020107008006A patent/KR101681909B1/ko active Active
- 2008-10-14 SI SI200831924T patent/SI2574629T1/en unknown
- 2008-10-14 MX MX2012010171A patent/MX363634B/es unknown
- 2008-10-14 PL PL12006791T patent/PL2574630T3/pl unknown
- 2008-10-14 EP EP12006791.3A patent/EP2574630B1/fr active Active
- 2008-10-14 NO NO12006789A patent/NO2574629T3/no unknown
- 2008-10-14 DK DK12006791.3T patent/DK2574630T3/en active
- 2008-10-14 PL PL08839958T patent/PL2205640T3/pl unknown
- 2008-10-14 ES ES12006791.3T patent/ES2679281T3/es active Active
- 2008-10-14 PT PT120067905T patent/PT2573121T/pt unknown
- 2008-10-14 CA CA3071750A patent/CA3071750C/fr active Active
- 2008-10-14 EP EP12006789.7A patent/EP2574629B1/fr active Active
- 2008-10-14 PT PT120067913T patent/PT2574630T/pt unknown
- 2008-10-15 TW TW106136056A patent/TW201825117A/zh unknown
- 2008-10-15 UY UY31394A patent/UY31394A1/es not_active Application Discontinuation
- 2008-10-15 TW TW097139453A patent/TWI619508B/zh active
- 2008-10-15 TW TW104112967A patent/TWI616206B/zh active
- 2008-10-15 TW TW104112966A patent/TWI616205B/zh active
- 2008-10-15 PA PA20088799001A patent/PA8799001A1/es unknown
2010
- 2010-03-22 TN TNP2010000126A patent/TN2010000126A1/fr unknown
- 2010-03-23 NI NI2010000402A patent/NI201000402A/es unknown
- 2010-03-23 NI NI2010000403A patent/NI201000403A/es unknown
- 2010-03-23 NI NI201000040A patent/NI201000040A/es unknown
- 2010-03-23 NI NI2010000406A patent/NI201000406A/es unknown
- 2010-03-23 NI NI2010000401A patent/NI201000401A/es unknown
- 2010-03-23 NI NI2010000404A patent/NI201000404A/es unknown
- 2010-03-23 NI NI2010000405A patent/NI201000405A/es unknown
- 2010-03-24 GT GT201000067A patent/GT201000067A/es unknown
- 2010-03-24 ZA ZA2010/02069A patent/ZA201002069B/en unknown
- 2010-03-25 MX MX2012002056A patent/MX354666B/es unknown
- 2010-03-25 CR CR11337A patent/CR11337A/es unknown
- 2010-04-11 IL IL205005A patent/IL205005A/en active IP Right Grant
- 2010-04-14 DO DO2010000109A patent/DOP2010000109A/es unknown
- 2010-04-14 HN HN2010000710A patent/HN2010000710A/es unknown
- 2010-05-10 MA MA32823A patent/MA31838B1/fr unknown
2012
- 2012-11-15 CL CL2012003196A patent/CL2012003196A1/es unknown
2013
- 2013-02-04 US US13/758,858 patent/US20130209469A1/en not_active Abandoned
- 2013-03-11 US US13/794,394 patent/US20130259866A1/en not_active Abandoned
- 2013-03-11 US US13/794,341 patent/US20130236461A1/en not_active Abandoned
- 2013-03-11 US US13/794,384 patent/US20130251718A1/en not_active Abandoned
- 2013-03-11 US US13/794,320 patent/US20130236460A1/en not_active Abandoned
- 2013-03-11 US US13/794,295 patent/US9738728B2/en active Active
- 2013-03-11 US US13/794,354 patent/US20130236462A1/en not_active Abandoned
- 2013-03-11 US US13/794,310 patent/US20130251717A1/en not_active Abandoned
- 2013-03-11 US US13/794,370 patent/US20130236463A1/en not_active Abandoned
- 2013-03-15 US US13/831,856 patent/US20130243776A1/en not_active Abandoned
- 2013-03-15 US US13/831,884 patent/US20130243778A1/en not_active Abandoned
- 2013-03-15 US US13/831,866 patent/US20140023649A1/en not_active Abandoned
- 2013-03-15 US US13/831,862 patent/US9732162B2/en active Active
- 2013-04-04 AU AU2013202389A patent/AU2013202389B9/en active Active
- 2013-04-10 AU AU2013203324A patent/AU2013203324C1/en active Active
- 2013-04-10 AU AU2013203339A patent/AU2013203339B9/en active Active
- 2013-04-10 AU AU2013203328A patent/AU2013203328B9/en active Active
- 2013-05-21 PH PH12013501032A patent/PH12013501032A1/en unknown
- 2013-05-21 PH PH12013501033A patent/PH12013501033B1/en unknown
- 2013-07-12 CL CL2013002039A patent/CL2013002039A1/es unknown
- 2013-07-12 CL CL2013002040A patent/CL2013002040A1/es unknown
- 2013-12-12 DO DO2013000301A patent/DOP2013000301A/es unknown
- 2013-12-12 DO DO2013000302A patent/DOP2013000302A/es unknown
2014
- 2014-02-20 CY CY20141100136T patent/CY1114987T1/el unknown
2015
- 2015-02-26 CR CR20150102A patent/CR20150102A/es unknown
- 2015-02-26 CR CR20150101A patent/CR20150101A/es unknown
- 2015-02-26 CR CR20150103A patent/CR20150103A/es unknown
- 2015-07-31 JP JP2015151694A patent/JP6126652B2/ja active Active
- 2015-07-31 JP JP2015151695A patent/JP6126653B2/ja active Active
- 2015-07-31 JP JP2015151693A patent/JP6280526B2/ja active Active
- 2015-09-29 RU RU2015141428A patent/RU2705551C2/ru active
- 2015-09-29 RU RU2015141418A patent/RU2721236C2/ru active
- 2015-12-10 CR CR20150654A patent/CR20150654A/es unknown
2016
- 2016-11-29 IL IL249289A patent/IL249289A0/en unknown
2017
- 2017-07-10 US US15/645,765 patent/US10759871B2/en active Active
- 2017-11-16 HR HRP20171765TT patent/HRP20171765T1/hr unknown
- 2017-11-22 CY CY20171101220T patent/CY1119875T1/el unknown
2018
- 2018-01-18 JP JP2018006055A patent/JP2018078907A/ja active Pending
- 2018-02-21 HR HRP20180320TT patent/HRP20180320T1/hr unknown
- 2018-02-22 CY CY20181100211T patent/CY1120033T1/el unknown
- 2018-03-27 HR HRP20180517TT patent/HRP20180517T1/hr unknown
- 2018-03-30 CY CY20181100360T patent/CY1120108T1/el unknown
- 2018-07-10 HR HRP20181085TT patent/HRP20181085T1/hr unknown
- 2018-07-17 CY CY181100741T patent/CY1120887T1/el unknown
- 2018-10-18 AR ARP180103042A patent/AR122833A2/es unknown
- 2018-10-18 AR ARP180103043A patent/AR122834A2/es unknown
2020
- 2020-07-28 US US16/941,272 patent/US11453727B2/en active Active
2022
- 2022-08-10 US US17/818,927 patent/US20230235088A1/en not_active Abandoned
2024
- 2024-12-12 US US18/978,951 patent/US20250313651A1/en active Pending

Also Published As

Publication number	Publication date
IL249289A0 (en)	2017-01-31
JP2016006086A (ja)	2016-01-14
EP2573115A1 (fr)	2013-03-27
HUE037205T2 (hu)	2018-08-28
PL2205640T3 (pl)	2014-05-30
AU2013203328B2 (en)	2017-01-05
RS53175B (sr)	2014-06-30
TR201810005T4 (tr)	2018-08-27
CA3015470A1 (fr)	2009-04-23
RS57060B1 (sr)	2018-05-31
RS56914B1 (sr)	2018-05-31
EP2050764A1 (fr)	2009-04-22
US9738728B2 (en)	2017-08-22
US20230235088A1 (en)	2023-07-27
US20130259866A1 (en)	2013-10-03
ZA201002069B (en)	2010-12-29
JP2018078907A (ja)	2018-05-24
US20130209469A1 (en)	2013-08-15
KR20100067669A (ko)	2010-06-21
PH12013501033A1 (en)	2015-05-25
NI201000402A (es)	2010-09-07
SI2205640T1 (sl)	2014-04-30
DK2574629T3 (en)	2018-02-26
KR20190022928A (ko)	2019-03-06
US8388965B2 (en)	2013-03-05
RU2015141418A (ru)	2017-04-04
US20130236461A1 (en)	2013-09-12
ES2679281T3 (es)	2018-08-23
US20180030156A1 (en)	2018-02-01
AU2013203324B2 (en)	2017-01-19
AU2008312655A1 (en)	2009-04-23
PT2573119T (pt)	2018-04-04
WO2009052081A3 (fr)	2009-06-04
JP6126653B2 (ja)	2017-05-10
CR20150103A (es)	2015-04-14
CY1120033T1 (el)	2018-12-12
US20140023649A1 (en)	2014-01-23
HRP20140150T1 (hr)	2014-03-28
CL2013002040A1 (es)	2014-01-24
DK2573119T3 (en)	2018-04-16
JP6280526B2 (ja)	2018-02-14
TW201536321A (zh)	2015-10-01
NZ601342A (en)	2014-02-28
PE20091382A1 (es)	2009-10-14
TWI619508B (zh)	2018-04-01
JP2011501671A (ja)	2011-01-13
IL205005A0 (en)	2010-11-30
HUE036530T2 (hu)	2018-07-30
US20130236460A1 (en)	2013-09-12
LT2574630T (lt)	2018-07-25
AR122834A2 (es)	2022-10-12
PT2205640E (pt)	2014-02-25
DK2573121T3 (en)	2017-12-04
SI2573121T1 (en)	2018-01-31
IL205005A (en)	2016-11-30
EP2573119A1 (fr)	2013-03-27
AU2013203328A1 (en)	2013-05-02
TWI616205B (zh)	2018-03-01
PL2574629T3 (pl)	2018-05-30
BRPI0818677A2 (pt)	2015-04-14
EP2574630B1 (fr)	2018-04-18
HRP20171765T1 (hr)	2017-12-29
JP2015231382A (ja)	2015-12-24
KR101823859B1 (ko)	2018-02-01
AU2008312655B2 (en)	2013-05-02
UY31394A1 (es)	2009-05-29
MX354150B (es)	2018-02-15
PH12013501032B1 (en)	2015-05-18
CL2012003196A1 (es)	2013-01-25
CL2013002039A1 (es)	2014-03-07
TW200932263A (en)	2009-08-01
EP2205640B1 (fr)	2013-11-20
EP2574629A1 (fr)	2013-04-03
JP6126652B2 (ja)	2017-05-10
EP2573118A1 (fr)	2013-03-27
RU2705551C2 (ru)	2019-11-07
RU2013120318A (ru)	2014-11-10
MX363634B (es)	2019-03-28
TW201825117A (zh)	2018-07-16
RU2488595C2 (ru)	2013-07-27
MX354666B (es)	2018-03-15
US20130251718A1 (en)	2013-09-26
US20130243776A1 (en)	2013-09-19
PT2574629T (pt)	2018-02-23
MX363638B (es)	2019-03-28
LT2573121T (lt)	2017-12-11
US20130236463A1 (en)	2013-09-12
NI201000403A (es)	2010-09-07
MA31838B1 (fr)	2010-11-01
PT2573121T (pt)	2017-11-21
RS57396B1 (sr)	2018-09-28
NZ709353A (en)	2018-06-29
CA3071750A1 (fr)	2009-04-23
CN106986938A (zh)	2017-07-28
EP3686220A1 (fr)	2020-07-29
HUE038444T2 (hu)	2018-10-29
GT201000067A (es)	2012-04-12
DOP2010000109A (es)	2010-05-31
EP2573121B1 (fr)	2017-08-23
RU2015141418A3 (fr)	2019-05-14
JP5858616B2 (ja)	2016-02-10
EP2573119B1 (fr)	2018-01-03
BRPI0818677B8 (pt)	2021-05-25
PT2574630T (pt)	2018-07-17
SG185303A1 (en)	2012-11-29
CN106986938B (zh)	2021-07-09
SG10201602770UA (en)	2016-05-30
US20210047437A1 (en)	2021-02-18
SI2574629T1 (en)	2018-03-30
PL2573119T3 (pl)	2018-07-31
CR20150101A (es)	2015-04-14
DK2574630T3 (en)	2018-07-30
RS56553B1 (sr)	2018-02-28
EP2574629B1 (fr)	2017-11-22
SI2573119T1 (en)	2018-05-31
AU2013202389A1 (en)	2013-05-02
US11453727B2 (en)	2022-09-27
CY1114987T1 (el)	2016-12-14
CY1120108T1 (el)	2018-12-12
NI201000404A (es)	2010-09-07
AU2013203339B9 (en)	2017-02-02
CY1119875T1 (el)	2018-06-27
AR068861A1 (es)	2009-12-09
AU2013202389B2 (en)	2017-01-05
NI201000405A (es)	2010-09-07
NI201000401A (es)	2010-09-07
TR201802225T4 (tr)	2018-03-21
EP2574630A1 (fr)	2013-04-03
KR20180014189A (ko)	2018-02-07
RU2721236C2 (ru)	2020-05-18
AU2013203324A1 (en)	2013-05-02
US9732162B2 (en)	2017-08-15
CL2008003037A1 (es)	2009-03-06
PL2573121T3 (pl)	2018-01-31
CN101827863A (zh)	2010-09-08
SG10201913836SA (en)	2020-03-30
RU2010119521A (ru)	2011-11-27
AU2013203339B2 (en)	2017-01-05
US20130243777A1 (en)	2013-09-19
LT2573119T (lt)	2018-04-10
CA3015470C (fr)	2022-01-18
EP2574626A1 (fr)	2013-04-03
KR101681909B1 (ko)	2016-12-05
NO2574629T3 (fr)	2018-04-21
ES2647872T3 (es)	2017-12-27
SG10201913838RA (en)	2020-03-30
DOP2013000301A (es)	2014-02-16
RU2580049C2 (ru)	2016-04-10
PH12013501033B1 (en)	2018-12-14
US20130236462A1 (en)	2013-09-12
KR20160142889A (ko)	2016-12-13
CA2702473C (fr)	2018-10-09
ES2660152T3 (es)	2018-03-21
TWI616206B (zh)	2018-03-01
JP2016006087A (ja)	2016-01-14
US20100226923A1 (en)	2010-09-09
AR122833A2 (es)	2022-10-12
AU2013203328B9 (en)	2017-02-02
EP2573121A1 (fr)	2013-03-27
SI2574630T1 (en)	2018-08-31
EP2205640A2 (fr)	2010-07-14
KR101954596B1 (ko)	2019-03-07
CR11337A (es)	2010-04-21
CA2702473A1 (fr)	2009-04-23
WO2009052081A2 (fr)	2009-04-23
NI201000040A (es)	2010-09-07
NZ584658A (en)	2012-08-31
US20130251716A1 (en)	2013-09-26
ES2447915T3 (es)	2014-03-13
HRP20180517T1 (hr)	2018-05-04
US20250313651A1 (en)	2025-10-09
LT2574629T (lt)	2018-03-12
WO2009052081A4 (fr)	2009-07-23
KR101682373B1 (ko)	2016-12-06
MX363901B (es)	2019-04-08
PL2574630T3 (pl)	2018-09-28
NO2573121T3 (fr)	2018-01-20
TW201536322A (zh)	2015-10-01
CR20150102A (es)	2015-04-30
AU2013202389B9 (en)	2017-02-02
RU2015141428A3 (fr)	2019-04-30
CN101827863B (zh)	2017-03-22
PA8799001A1 (es)	2009-07-23
MX2010003290A (es)	2010-04-30
CN113480647B (zh)	2025-03-28
RU2015141428A (ru)	2017-04-04
US20130243778A1 (en)	2013-09-19
NI201000406A (es)	2010-09-07
HRP20181085T1 (hr)	2018-09-07
ES2664476T3 (es)	2018-04-19
EP2573117A1 (fr)	2013-03-27
CA3071750C (fr)	2022-06-14
US10759871B2 (en)	2020-09-01
UA104130C2 (uk)	2014-01-10
NZ729148A (en)	2021-12-24
CR20150654A (es)	2016-02-08
BRPI0818677B1 (pt)	2019-11-12
DOP2013000302A (es)	2014-02-16
HRP20180320T1 (hr)	2018-04-06
HN2010000710A (es)	2013-07-22
UA118949C2 (uk)	2019-04-10
AU2013203339A1 (en)	2013-05-02
CY1120887T1 (el)	2019-12-11
DK2205640T3 (en)	2014-02-24
HUE038556T2 (hu)	2018-10-29
KR20140112574A (ko)	2014-09-23
US20130251717A1 (en)	2013-09-26
MY171214A (en)	2019-10-02
AU2013203324C1 (en)	2017-03-30
PH12013501032A1 (en)	2015-05-18
CN113480647A (zh)	2021-10-08
EP2573116A1 (fr)	2013-03-27

Publication	Publication Date	Title
MY171214A (en)	2019-10-02	Antibodies that bind il-4 and/or il-13 and their uses
MY162511A (en)	2017-06-15	Engineered anti-tslp antibody
JO3097B1 (ar)	2017-03-15	الأجسام المضادة c-Met
TW200736274A (en)	2007-10-01	Immunoglobulins
MX2009010765A (es)	2009-10-26	Anticuerpos anti-ige.
PH12013500356A1 (en)	2021-08-09	Engineered anti-tslp antibody
WO2010032059A3 (fr)	2010-06-24	Agents de liaison ciblés dirigés sur cd105 et leurs utilisations
TW200736275A (en)	2007-10-01	Methods and compositions for treating allergic diseases
TN2009000529A1 (en)	2011-03-31	Methods and compositions for treating allergic diseases
PH12012501761A1 (en)	2012-11-12	Anti-nerve growth factor (ngf) antibody compositions
MX2009008410A (es)	2009-08-18	Elementos de aglutinacion para moleculas de ige.
PH12012500828A1 (en)	2013-01-07	Compositions and methods for treating inflammatory disorders
UA104739C2 (en)	2014-03-11	c-MET ANTIBODIES